Diamond Therapeutics

The promise of a new and better class of mental health therapies lies within the chemistry of psychedelic compounds. Our mission is to unlock it.

[Diamond Therapeutics @DiamondThera]

Diamond is pleased to announce a strategic investment round led by First Avenue Ventures Life Science Fund I. https://t.co/WTjuEMCKKp

[UAB School of Public Health @uabsoph]

@uabnews and @DiamondThera have announced a collaboration, researching low doses of psilocybin to treat demoralization. @uabsoph professor Peter Hendricks, PhD is principle investigator in this five-week randomized clinical trial. Read more at https://t.co/BFHglJkMGI

[Diamond Therapeutics @DiamondThera]

Diamond is excited to announce our FDA-authorized clinical trial of low-dose psilocybin in collaboration with the University of Alabama at Birmingham.
https://t.co/C0nkavO78d

[Diamond Therapeutics @DiamondThera]

@afelicelli @WovenScience Hi Antoine. We want to DM you a contact email.

[Diamond Therapeutics @DiamondThera]

“Anxiety is the most common psychiatric disorder,” says Judy Blumstock, Diamond’s chief executive. “And the existing treatments aren’t satisfactory.” https://t.co/wciDckypVU

[Bell Let's Talk @Bell_LetsTalk]

Today is #BellLetsTalk Day! One of the ways we can all take action is to learn about mental health organizations creating positive change for mental health in Canada…every day.

[Microdose Psychedelic Insights @MicrodoseHQ]

Diamond’s Phase 2 trial has been approved by Health Canada, a Phase 2 randomized, double-blind study in adult patients with Generalized Anxiety Disorder. Patients will receive repeat low doses of psilocybin administered on a take-home basis.

@DiamondThera
https://t.co/wcTnCex610

[Diamond Therapeutics @DiamondThera]

Diamond has received Health Canada approval to begin a Phase 2 clinical trial evaluating the safety, tolerability and efficacy of repeat low doses of psilocybin for the treatment of generalized anxiety disorder (GAD). https://t.co/9WCuT6vcyH

[Diamond Therapeutics @DiamondThera]

Thank you, Roland Griffiths, for all you've done and continue to do to advance psychedelic science.

[Diamond Therapeutics @DiamondThera]

“The purpose of this endowment is to support a professorship and to establish a world class, rigorous, empirical program of research with psychedelic substances..”https://t.co/qrlKlBhXii

[Diamond Therapeutics @DiamondThera]

Excited to see our Phase 1 trial results and the potential for take-at-home psychedelic-derived drugs covered by Benzinga! https://t.co/DWwi6X94Eu

[Diamond Therapeutics @DiamondThera]

Read the full release here: https://t.co/534N5Tdfk8

[Diamond Therapeutics @DiamondThera]

And thanks to Chef for this whimsical dessert!

[Diamond Therapeutics @DiamondThera]

Thank you, Dr. Emma Hapke, Dr. Daniel Rosenbaum, Dr. Susan Abbey, Nikean Foundation and @uhnfoundation, for a lively evening at The York Club.

[Diamond Therapeutics @DiamondThera]

Diamond CEO Judy Blumstock discusses all things low-dose psilocybin with The Tonic. https://t.co/oPGCjzxDnU

[Diamond Therapeutics @DiamondThera]

Exciting news. Wishing all GEEKs much success!!

[Ontario Brain Institute @OntarioBrain]

The 2022 OBI GEEKs have been chosen! First up, we have Health Nexus Santé: The Indigenous Brain Story creating a revised curriculum for brain neuroscience training. Learn more about the 2022 GEEKs here > https://t.co/Pk1P25HI8N

#meettheGEEKs #indigenousbrainhealth #community

[Business Trip @businesstripfm]

New episode: Microdosing (Part 3)!

We discuss the path to FDA approval with...

Dr. Dan Karlin: MindMed (LSD for adult ADHD)
and
Dr. Mike McDonnell: Diamond Therapeutics (psilocybin for anxiety disorders)

Tune in here: https://t.co/cfdBV3ZXF9

@mindmedco @DiamondThera

[Michael Pollan @michaelpollan]

For those looking for more information about psychedelics and psychedelic therapy, check out the Berkeley Center’s new resources website, https://t.co/6K1TfYHecy

[Business Trip @businesstripfm]

In part 2 (out next week), we discuss the placebo effect and results from a placebo controlled microdosing study from @psybalazs @imperialcollege.

In part 3, we talk w/ the chief medical officers of @mindmedco @DiamondThera about going for FDA approval for microdosing.

[Diamond Therapeutics @DiamondThera]

5/5
@DiamondThera science advisory chair Dr. Ed Sellers outlines the challenges of testing #psychedelics in human subjects in the International Journal of Pharmacology’s special issue on psychedelic science. https://t.co/hMj4rYVzOf

[Diamond Therapeutics @DiamondThera]

1/5 If you’re enjoying @michaelpollan’s #HowToChangeYourMind on @netflix and want to go deeper on the science, here’s a list of #psychedelic readings authored by @DiamondThera advisors, collaborators and team members:

[Diamond Therapeutics @DiamondThera]

4/5 In this episode of @ProfDavidNutt's @Drug_Science
Podcast, @DiamondThera advisor Dr. Paul Glue discusses the development of oral ketamine and his hope that it can become an at-home vs. in-clinic treatment. https://t.co/ss9Xjejs0D